Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

Summary

The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with metastatic or unresectable pancreas cancer. Participants receive 8 twice weekly doses and then 8 more doses every 2 weeks of EGFR FPBMC by intravenous infusion.

Timeline

Start

2024-11-06

Primary completion

2027-12

Completion

2031-06

Drugs

Indications